Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Debt (2022)

Century Therapeutics (IPSC) has disclosed Non-Current Debt for 1 consecutive years, with $3.7 million as the latest value for Q4 2022.

  • On a quarterly basis, Non-Current Debt changed N/A to $3.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $3.7 million, a N/A change, with the full-year FY2022 number at $3.7 million, changed N/A from a year prior.
  • Non-Current Debt was $3.7 million for Q4 2022 at Century Therapeutics, down from $6.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $10.0 million in Q1 2022 to a low of $3.7 million in Q4 2022.